Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

DYNAMIC-III: ctDNA that remained positive after treatment marked a much higher recurrence risk

In the same DYNAMIC-III analysis published in Nature Medicine on October 20, 2025, patients with stage III colon cancer whose ctDNA stayed positive after treatment had a 3-year recurrence-free survival of 14%, compared with 79% among patients who cleared ctDNA.

Nature Medicine